Danaher

The test, which uses automated reverse-transcription real-time PCR, expands the firm's menu of CLIA-waived tests for use in near-patient and point-of-care settings.

The company's Life Sciences segment was up 17 percent year over year, while its Diagnostics business grew 8 percent.

The company's Diagnostics business was up 14 percent, while its Life Sciences business grew 13 percent. The firm also closed its $2 billion buy of IDT last week.

The company will use a portion of the credit facility to fund its announced acquisition of Integrated DNA Technologies.

Danaher said that it expects its first quarter adjusted EPS to exceed the high end of its previous guidance. During its Q4 2017 and full-year 2017 earnings announcement in January, the company said that adjusted EPS for Q1 2018 was anticipated to be in the range of $.90 to $.93.

IDT will operate as a standalone company within Danaher's Life Sciences segment after the close of the deal, which is expected to occur in mid-2018.